Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.44 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.40 |
| ▸ | NUDT1 | P36639 | 4/20 | 0.40 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | PRKACA | P17612 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.36 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2036679 | 1.00 | POLB (0.46) | POLBHRH3TLR8HRH4NUDT1 | |
| SCHEMBL2036582 | 1.00 | POLB (0.46) | POLBHRH3TLR8HRH4NUDT1 | |
| SCHEMBL21556891 | 0.82 | POLB (0.51) | POLBHRH3TLR8HRH4NUDT1 | |
| SCHEMBL2031722 | 0.81 | POLB (0.50) | POLBHRH3TLR8HRH4NUDT1 | |
| SCHEMBL2033811 | 0.80 | POLB (0.53) | POLBHRH3TLR8HRH4NUDT1 | |
| SCHEMBL2032932 | 0.80 | POLB (0.53) | POLBHRH3TLR8HRH4NUDT1 | |
| SCHEMBL2039822 | 0.80 | POLB (0.53) | POLBHRH3TLR8HRH4NUDT1 | |
| SCHEMBL20819339 | 0.78 | TLR8 (0.51) | POLBHRH3TLR8HRH4NUDT1 | |
| SCHEMBL20819330 | 0.78 | TLR8 (0.51) | POLBHRH3TLR8HRH4NUDT1 | |
| SCHEMBL83993 | 0.75 | POLB (0.56) | POLBHRH3TLR8HRH4NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2516397-B1 | Amino-heteroaryl derivatives as HCN blockers | MERCK SHARP & DOHME (NL) | 2016-07-13 | — | — | EP | disclosed |
| US-8952001-B2 | Amino-heteroaryl derivatives as HCN blockers | MERCK SHARP & DOHME CORP. (US) | 2015-02-10 | — | — | US | disclosed |
| CN-102884048-B | Amino-heteroaryl derivatives as HCN blockers | MSD OSS BV | 2014-07-23 | — | — | CN | disclosed |
| CN-102884048-A | Amino-heteroaryl derivatives as HCN blockers | MSD OSS BV | 2013-01-16 | — | — | CN | disclosed |
| EP-2516397-A1 | AMINO-HETEROARYL DERIVATIVES AS HCN BLOCKERS | MSD Oss B.V. (NL) | 2012-10-31 | — | — | EP | disclosed |
| US-20120264728-A1 | AMINO-HETEROARYL DERIVATIVES AS HCN BLOCKERS | ORGANON BIOSCIENCES NEDERLAND B.V. (NL) | 2012-10-18 | — | — | US | disclosed |
| WO-2011076723-A1 | AMINO-HETEROARYL DERIVATIVES AS HCN BLOCKERS | N.V. ORGANON (NL) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264728-A1 | AMINO-HETEROARYL DERIVATIVES AS HCN BLOCKERS | HCN1, HCN3, HCN2 | POLB 3931/4885HRH3 113/4885TLR8 3166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.